The treatment of patients with advanced lung cancer associated with EGFR mutation


Cite item

Full Text

Abstract

In this article we produce present practice in treatment of advanced stages of non-small cell lung cancer with activating mutations in EGFR genes. Describe opportunities of effective using of target agents in these cases. There are notions about mechanisms of resistance for target therapy, and demonstrate different approach in this field.

About the authors

L V Bolotina

P.A.Herzen Moscow Research Institute of Oncology of National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation

Email: lbolotina@yandex.ru
д-р мед. наук, рук. отд-ния химиотерапии МНИОИ им. П.А.Герцена - филиала ФГБУ НМИРЦ 125284, Russian Federation, Moscow, 2-i Botkinskii pr., d. 3

References

  1. Каприн А.Д., Старинский В.В. и др. Состояние онкологической помощи населению России в 2014 году. М., 2015.
  2. Chemotherapy in non - small cell lung cancer: a meta - analysis using updated data on individual patients from 52 randomised clinical trials. Non - small cell Lung Cancer Collaborative Group. BMJ 1995; 311: 889-909.
  3. Ciuleanu T et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non - small - cell lung cancer: a randomised, double - blind, phase 3 study. Lancet 2009; 374: 1432-40.
  4. Schiller J.H et al. Comparison of four chemotherapy regimens for advanced non - small - cell lung cancer. N. Engl J Med 2002; 346: 92-8.
  5. Sandler A et al. Paclitaxel - carboplatin alone or with bevacizumab for non - small - cell lung cancer. N Engl J Med 2006; 355: 2542-50.
  6. Scagliotti G et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009; 14: 253-63.
  7. Fukuoka M et al. Biomarker analyses and final overall survival results from a phase III, randomized, open - label, first - line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small - cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29: 2866-74.
  8. Reck M et al. Management of non - small - cell lung cancer: recent developments. Lancet 2013; 382: 709-19.
  9. Cheng L et al. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol 2012; 25: 347-69.
  10. Harris T.J, Mc Cormick F. The molecular pathology of cancer. Nat Rev Clin Oncol 2010; 7: 251-65.
  11. Seshacharyulu P et al. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16: 15-31.
  12. Yarden Y et al. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.
  13. Baselga J et al. Epithelial growth factor receptor interacting agents. Hematol Oncol Clin North Am 2002; 16: 1041-63.
  14. Herbst R.S et al. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin Invest Drugs 2002; 11: 837-49.
  15. Arteaga C.L. EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. Cancer Cell 2006; 9: 421-3.
  16. Gazdar A.F et al. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med 2004; 10: 481-6.
  17. Hendricks B.S et al. Decreased internalisation of erbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib. Systems Biology 2006; 153: 457-66.
  18. Sordella R et al. Gefitinib - sensitizing EGFR mutations in lung cancer activate anti - apoptotic pathways. Science 2004; 305: 1163-7.
  19. Tjulandin S et al. Prospective cohort study of clinical characteristics and management patterns for patients with non - small - cell lung cancer in the Russian Federation: EPICLIN-Lung. Curr Med Res Opin 2015; 31 (6): 1117-27.
  20. Sharma S.V et al. Epidermal growth factor receptor mutations in lung cancer. Nature Rev Cancer 2007; 7: 169-81.
  21. Rosell R et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361 (10): 958-67.
  22. Mok T.S et al. Gefitinib or carboplatin - paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
  23. Моисеенко В.М., Проценко С.А., Семенов И.И. Применение Ирессы (гефитиниба) в качестве терапии первой линии для лечения неоперабельных аденокарцином легкого, содержащих мутацию в гене EGFR // Современная онкология. 2010; 12 (1): 60-6.
  24. Stewart E.L et al. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations - a review. Transl Lung Cancer Res 2015; 4 (1): 67-81.
  25. Практические рекомендации по лечению злокачественных опухолей. URL: http://www.rosoncoweb.ru/standarts/RUSSCO/ 01.pdf
  26. NCCN Guidelines. URL: http://www.nccn.org/ professionals/ physician gls/pdf/nscl.pdf
  27. Reck M et al. Metastatic non - small - cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow - up. Ann Oncol 2014; 25 (Suppl. 3): iii27-39.
  28. Leighl N.B et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol 2014; 32 (32): 3673-9.
  29. Горбунова В.А., Артамонова Е.В., Бредер В.В. и др. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого. Злокачественные опухоли. 2016; 4. (Спецвып. 2): 22-33.
  30. Johnson B.E et al. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2013; 31 (Suppl.): abstr. 8019.
  31. Maemondo M et al. Gefitinib or chemotherapy for non - small - cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8.
  32. Mitsudomi T et al. Gefitinib versus cisplatin plus docetaxel in patients with non - small - cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-8.
  33. Lin J.J et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol 2016; 11 (4): 556-65.
  34. Scagliotti G.V et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy - naive patients with advanced - stage non - small - cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
  35. Zhang L et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non - small - cell lung cancer (INFORM; C-TONG 0804): a multicentre, double - blind randomised phase 3 trial. Lancet Oncol 2012; 13 (5): 466-75.
  36. Burotto M et al. Gefitinib and erlotinib in metastatic non - small cell lung cancer: a meta - analysis of toxicity and efficacy of randomized clinical trials. Oncologist 2015; 20: 400-10.
  37. Park K et al. Afatinib versus gefitinib as first - line treatment of patients with EGFR mutation - positive non - small - cell lung cancer (LUX-Lung 7): a phase 2B, open - label, randomised controlled trial. Lancet Oncol 2016; 17: 577-89.
  38. Park K et al. First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study. JAMA Oncol 2016; 2 (3): 305-12.
  39. Weickhardt A.J et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene - addicted non - small - cell lung cancer. J Thorac Oncol 2012; 7 (12): 1807-14.
  40. Cortot A.B, Jänne P.A. Molecular mechanisms of resistance in epidermal growth factor receptor - mutant lung adenocarcinomas. Eur Respir Rev 2014; 23 (133): 356-66.
  41. Jackman D et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non - small - cell lung cancer. J Clin Oncol 2010; 28 (2): 357-60.
  42. Yu H.A et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19: 2240-7.
  43. Oxnard G.R et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011; 17 (6): 1616-22.
  44. Sun J.M et al. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer 2013; 82: 294-8.
  45. Kuiper J.L et al. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Lung Cancer 2014; 85: 19-24.
  46. Li W et al. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. Lung Cancer 2014; 84: 295-300.
  47. Kobayashi S et al. EGFR mutation and resistance of non - small - cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-92.
  48. Cross D.A et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046-61.
  49. Yun C.H et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008; 105: 2070-5.
  50. Kris M.G et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311 (19): 1998-2006.
  51. Fukuoka M et al. Multi - institutional randomized phase II trial of gefitinib for previously treated patients with advanced non - small - cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21 (12): 2237-46.
  52. Kris M.G et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non - small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-58.
  53. Mok T, Yang J.J, Lam K.C. Treating patients with EGFR-sensitizing mutations: first line or second line -- is there a difference? J Clin Oncol 2013; 31 (8): 1081-8.
  54. Park K. LUX-Lung 7: is there enough data for a final conclusion? Lancet Oncol 2016; 17 (7): e268-9.
  55. Sequist L.V et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31 (27): 3327-34.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies